The residual megakaryocyte and platelet production in c-Mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor

Blood

Volumn 95, Issue 2, 2000, Pages 528-534

  Gainsford, Timothy ^a,b   Nandurkar, Marshal ^a   Metcalf, Donald ^a   Robb, Lorraine ^a   Glenn Begley, C ^a   Alexander, Warren S ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 11; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; THROMBOPOIETIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HEMOSTASIS; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STEM CELL; THROMBOCYTOPOIESIS;

EID: 0034650935     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.2.528     Document Type: Article

References (40)

1. Banu N, Wang JF, Deng B, Groopman JE, Avraham H. Modulation of megakaryocytopoiesis by thrombopoietin: the c-MpI ligand. Blood. 1995;86: 1331-1338.
2. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erytnropoietin, stem cell factor, and interteukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 1995:85:1719-1726.
3. Hunt P, U YS, Nichol JL, et al. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood. 1995:86:540-547.
4. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-MpI ligand thrombopoietin [see comments]. Nature. 1994:369:568-571.
5. Zeigler FC, de Sauvage F, Widmer HR, et al. In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood. 1994:84:40454052.
6. Debili N, Wendung F, Katz A, et al. The Mpl-Iigand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood. 1995;86:25162525.
7. Choi ES, Hokom M, BartleyT, et al. Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-MpI, produces functional human platelets in vitro. Stem Cells. 1995;13:317-322.
8. Norol F, Vitrât N, Cramer E, et al. Effects of cytokines on platelet production from blood and marrow CD34+ cells. Blood. 1998:91:830-843.
9. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo [see comments]. Nature. 1994:369:565-568.
10. Ulich TR, del Castillo J, Yin S, et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood. 1995:86:971-976.
11. Farese AM, Hunt P, Boone T, MacVittie TJ. Re-combinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood. 1995; 86:54-59.
12. Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 1996;348:1279-1281.
13. de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med. 1996:183:651-656.
14. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science. 1994;265:1445-1447.
15. Alexander WS, Roberts AW, Nicola NA, U R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietlc lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood. 1996;87:2162-2170.
16. Metcalf D, Begley CG, Johnson GR, Nicola NA, Lopez AF, Wiiliamson DJ. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood. 1986; 68:46-57.
17. Gainsford T, Roberts AW, Kimura S, et al. Cytokine production and function in c-mpl-deficient mice: no physiologic role for interteukin-3 in residual megakaryocyte and platelet production. Blood. 1998:91:2745-2752.
18. Mach N, Lantz CS, Galli SJ, et al. Involvement of interleukin-3 in delayed-type hypersensitivity. Blood. 1998;91:778-783.
19. Chen Q, Solar G, Eaton DL, De Sauvage FJ. IL-3 does not contribute to platelet production in c-Mpl deficient mice. Stem Cells. 1998;16 (supp 2): 21-36.
20. Metcalf D, Burgess AW, Johnson GR, et al. In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GMCSF. J Cell Physiol. 1986:128:421-431.
21. Gordon MS, Hoffman R. Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood. 1992; 80:302-307.
22. Taga T, Kishimoto T. Gp130 and the interteukin-6 family of cytokines. [Review] [130 refs]. Annu Rev Immunol. 1997:15:797-819.
23. Huffman R. The rote of other haemopoietic growth factors and the marrow microenvironment in megakaryocytopoiesis. In: Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D (eds). Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical and Clinical Biology. Totowa, NJ: Humana Press, Inc; 1997:165-180.
24. Ishibashi T, Kimura H, Uchida T, anyone S, Friese P, Burstein SA. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sei USA. 1989;86:59535957.
25. Burstein SA, Mei RL, Henthorn J, Friese P, Turner K. Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol. 1992;153:305312.
26. Ishibashi T, Kimura H, Shikama Y, et al. Interteukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 1989;74:1241-1244.
27. Metcalf D, Nicola NA, Gearing DP. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood. 1990;76:50-56.
28. Neben TY, Loebelenz J, Hayes L, et al. Recombinant human interieukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood. 1993; 81:901-908.
29. Bemad A, Kopf M, Kulbacki R, Weich N, Koehler G, Gutierrez-Ramos JC. Interteukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity. 1994:1:725-731.
30. Escary JL, Perreau J, Dumenil D, Ezine S, Brütet P. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature. 1993:363:361364.
31. Nandurkar HH, Robb L, Tartinton D, Bamett L, Kontgen F, Begley CG. Adult mice with targeted mutation of the interteukin-11 receptor (IL11 Ra) display normal hematopoiesis. Blood. 1997;90: 2148-2159.
32. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin6-deficient mice. Nature. 1994;368:339-342.
33. Yoshida K, Taga T, Saito M, et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Nail Acad SciUSA. 1996;93:407-411.
34. Betz UAK, Bloch W, van den Broek M, et al. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, im-munological, hepatic, and pulmonary defects. J Exp Med. 1998:188:1955-1965.
35. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell. 1995:81:695-704.
36. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93: 2867-2875.
37. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16:3965-3973.
38. Wu H, LJU X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Ceil. 1995:83:59-67.
39. Kimura S, Roberts AW, Metcalf D, Alexander WS. Hematopoietic stem ceil deficiencies in mice lacking c-MpI, the receptor for thrombopoietin. Proc Natl Acad Sei USA. 1998:95:1195-1200.
40. Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood. 1998:92:4-10.